Patents by Inventor Michael J. MASSARE

Michael J. MASSARE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Highly efficient influenza matrix (M1) proteins
    Patent number: 10544399
    Abstract: This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: January 28, 2020
    Assignee: Novavax, Inc.
    Inventors: Gale Smith, Yingyun Wu, Michael J. Massare, Peter M. Pushko, Margaret Nathan, Thomas Kort, Robin Robinson
  • Vaccine compositions having improved stability and immunogenicity
    Patent number: 10426829
    Abstract: Disclosed herein are nanoparticles suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: October 1, 2019
    Assignee: Novavax, Inc.
    Inventors: Gale Smith, Ye Liu, Jing-Hui Tian, Michael J. Massare, Sarathi Boddapati, Erica Shane, Cynthia Oliver, Gregory Glenn
  • MODIFIED RSV F PROTEINS AND METHODS OF THEIR USE
    Publication number: 20190134187
    Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
    Type: Application
    Filed: June 15, 2018
    Publication date: May 9, 2019
    Inventors: Peter M. PUSHKO, Yingyun WU, Michael J. MASSARE, Ye LIU, Gale SMITH, Bin ZHOU
  • HIGHLY EFFICIENT INFLUENZA MATRIX (M1) PROTEINS
    Publication number: 20190062713
    Abstract: This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.
    Type: Application
    Filed: March 22, 2018
    Publication date: February 28, 2019
    Inventors: Gale SMITH, Yingyun WU, Michael J. MASSARE, Peter M. PUSHKO, Margaret NATHAN, Thomas KORT, Robin ROBINSON
  • Modified RSV F proteins and methods of their use
    Patent number: 10022437
    Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: July 17, 2018
    Assignee: NOVAVAX, INC.
    Inventors: Peter Pushko, Yingyun Wu, Michael J. Massare, Ye Liu, Gale Smith, Bin Zhou
  • VACCINE COMPOSITIONS HAVING IMPROVED STABILITY AND IMMUNOGENICITY
    Publication number: 20180133308
    Abstract: Disclosed herein are nanoparticles suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Application
    Filed: November 21, 2017
    Publication date: May 17, 2018
    Applicant: Novavax, Inc.
    Inventors: Gale SMITH, Ye LIU, Jing-Hui TIAN, Michael J. MASSARE, Sarathi BODDAPATI, Erica SHANE, Cynthia OLIVER, Gregory GLENN
  • Highly efficient influenza matrix (M1) proteins
    Patent number: 9951317
    Abstract: This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: April 24, 2018
    Assignee: NOVAVAX, INC.
    Inventors: Gale Smith, Yingyun Wu, Michael J. Massare, Peter M. Pushko, Margaret Nathan, Thomas Kort, Robin Robinson
  • VACCINE COMPOSITIONS CONTAINING MODIFIED ZIKA VIRUS ANTIGENS
    Publication number: 20170354729
    Abstract: The present disclosure relates to vaccine compositions that comprise a Zika virus antigen and an adjuvant. The present disclosure also provides methods for inducing a protective immune response by administering the disclosed vaccine compositions in a subject in needs thereof. The present methods also comprise the binding of the Zika virus vaccine to Zika virus cellular receptor proteins.
    Type: Application
    Filed: March 16, 2017
    Publication date: December 14, 2017
    Inventors: Ye LIU, Jing-Hui TIAN, Gale SMITH, Michael J. MASSARE, Sarathi BODDAPATI
  • HIGHLY EFFICIENT INFLUENZA MATRIX (M1) PROTEINS
    Publication number: 20170253861
    Abstract: This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.
    Type: Application
    Filed: October 6, 2016
    Publication date: September 7, 2017
    Inventors: Gale SMITH, Yingyun WU, Michael J. MASSARE, Peter M. PUSHKO, Margaret NATHAN, Thomas KORT, Robin ROBINSON
  • Modified RSV F proteins and methods of their use
    Patent number: 9731000
    Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: August 15, 2017
    Assignee: Novavax, Inc.
    Inventors: Peter M. Pushko, Yingyun Wu, Michael J. Massare, Ye Liu, Gale Smith, Bin Zhou
  • Modified RSV F proteins and methods of their use
    Patent number: 9717786
    Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: August 1, 2017
    Assignee: Novavax, Inc.
    Inventors: Peter M. Pushko, Yingyun Wu, Michael J Massare, Ye Liu, Gale Smith, Bin Zhou
  • VACCINE COMPOSITIONS HAVING IMPROVED STABILITY AND IMMUNOGENICITY
    Publication number: 20170202948
    Abstract: Disclosed herein are nanoparticles suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Application
    Filed: September 6, 2016
    Publication date: July 20, 2017
    Applicant: NOVAVAX, INC.
    Inventors: Gale SMITH, Ye Liu, Jing-Hui TIAN, Michael J. MASSARE, Sarathi BODDAPATI, Erica SHANE, Cynthia Oliver, Gregory GLENN
  • Modified RSV F proteins and methods of their use
    Patent number: 9675685
    Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: June 13, 2017
    Assignee: NOVAVAX, INC.
    Inventors: Peter Pushko, Yingyun Wu, Michael J. Massare, Ye Liu, Gale Smith, Bin Zhou
  • MODIFIED RSV F PROTEINS AND METHODS OF THEIR USE
    Publication number: 20150266930
    Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
    Type: Application
    Filed: June 4, 2015
    Publication date: September 24, 2015
    Inventors: Peter PUSHKO, Yingyun Wu, Michael J. Massare, Ye Liu, Gale Smith, Bin Zhou
  • MODIFIED RSV F PROTEINS AND METHODS OF THEIR USE
    Publication number: 20150265698
    Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
    Type: Application
    Filed: June 4, 2015
    Publication date: September 24, 2015
    Inventors: Peter PUSHKO, Yingyun Wu, Michael J. Massare, Ye Liu, Gale Smith, Bin Zhou
  • MODIFIED RSV F PROTEINS AND METHODS OF THEIR USE
    Publication number: 20140294879
    Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
    Type: Application
    Filed: March 21, 2014
    Publication date: October 2, 2014
    Applicant: NOVAVAX, INC.
    Inventors: Peter PUSHKO, Yingyun WU, Michael J. MASSARE, Ye LIU, Gale SMITH, Bin ZHOU
  • ENHANCED EXPRESSION OF PICORNAVIRUS PROTEINS
    Publication number: 20140271697
    Abstract: The disclosure provides fusion proteins containing N-terminal signal peptides fused to immunogenic polypeptides. The immunogenic polypeptides may be from viruses, bacteria, or fungi. The disclosure also provides elevated expression of the immunogenic polypeptides using the N-terminal signal peptide. The N-terminal signal peptides enhance synthesis of the protein, particularly where the protein is neither a secretory nor a transmembrane peptide. The fusion proteins may be used to diagnose disease and to induce immune responses.
    Type: Application
    Filed: March 10, 2014
    Publication date: September 18, 2014
    Applicant: NOVAVAX, INC.
    Inventor: Michael J. MASSARE